Exciting news for the small cell community! Yesterday, the FDA granted accelerated approval for a new treatment, Imdelltra (tarlatamab-dlle), for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy.
The approval is based on results from the DeLLphi-301 trial and showed people receiving Imdelltra (tarlatamab-dlle) generally received some meaningful benefit from the therapy sustained over several months.
Imdelltra (tarlatamab-dlle) is a new type of treatment for ES-SCLC known as a bi-specific T-cell engager. This type of therapy helps a person’s immune system identify and attack cancer cells in the body by binding to targets on both T-cells (a type of immune cell in the body) and the cancer itself. Imdelltra (tarlatamab-dlle) targets a protein on the surface of T-cells known as CD3 and a protein found on the surface of cancer cells known as DLL3, which is found in over 85% of people with SCLC.
Here's the link to read more: go2.org/blog/fda-approves-i...
